The FDA approved obinutuzumab (Gazyva) for reducing relapse risk in patients aged 2 and older with frequently relapsing idiopathic nephrotic syndrome.
2
Idiopathic nephrotic syndrome causes urinary protein loss, low blood albumin, and can lead to complications like high cholesterol and infections.
3
The condition primarily affects pediatric patients, typically developing between ages 2 and 7, with an annual incidence of 1 to 4 cases per 100,000.
4
Efficacy of obinutuzumab was evaluated in the INSHORE trial, showing a statistically significant improvement over standard treatment.
5
Obinutuzumab carries warnings for hepatitis B virus reactivation and progressive multifocal leukoencephalopathy, with common side effects including infections.
Investigators linked distinct odor patterns to life stage, sex, and skin microbes, while limited longitudinal evidence leaves their clinical utility uncertain.